Prospective study of cutaneous adverse effects associated with BRAF inhibitor dabrafenib and MEK inhibitor trametinib: A study of 12 patients

被引：0
|
作者：
Lacroix, Jean-Philip [1 ]
Wang, Beatrice [2 ]
Mihalciouiu, Catalin [2 ]
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] McGill Univ, Royal Victoria Hosp, Montreal, PQ, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
3300
引用
收藏
页码：AB68 / AB68
页数：1
相关论文
共 50 条
  • [1] Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
    Lacroix, Jean-Philip
    Wang, Beatrice
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2017, 21 (01) : 54 - 59
  • [2] Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
    Boussemart, L.
    Routier, E.
    Mateus, C.
    Opletalova, K.
    Sebille, G.
    Kamsu-Kom, N.
    Thomas, M.
    Vagner, S.
    Favre, M.
    Tomasic, G.
    Wechsler, J.
    Lacroix, L.
    Robert, C.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1691 - 1697
  • [3] Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
    Kim, Kevin B.
    Kefford, Richard
    Pavlick, Anna C.
    Infante, Jeffrey R.
    Ribas, Antoni
    Sosman, Jeffrey A.
    Fecher, Leslie A.
    Millward, Michael
    McArthur, Grant A.
    Hwu, Patrick
    Gonzalez, Rene
    Ott, Patrick A.
    Long, Georgina V.
    Gardner, Olivia S.
    Ouellet, Daniele
    Xu, Yanmei
    DeMarini, Douglas J.
    Le, Ngocdiep T.
    Patel, Kiran
    Lewis, Karl D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 482 - 489
  • [4] Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    Autier, Julien
    Escudier, Bernard
    Wechsler, Janine
    Spatz, Alain
    Robert, Caroline
    ARCHIVES OF DERMATOLOGY, 2008, 144 (07) : 886 - 892
  • [5] Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
    Johnson, Douglas B.
    Flaherty, Keith T.
    Weber, Jeffrey S.
    Infante, Jeffrey R.
    Kim, Kevin B.
    Kefford, Richard F.
    Hamid, Omid
    Schuchter, Lynn
    Cebon, Jonathan
    Sharfman, William H.
    McWilliams, Robert R.
    Sznol, Mario
    Lawrence, Donald P.
    Gibney, Geoffrey T.
    Burris, Howard A., III
    Falchook, Gerald S.
    Algazi, Alain
    Lewis, Karl
    Long, Georgina V.
    Patel, Kiran
    Ibrahim, Nageatte
    Sun, Peng
    Little, Shonda
    Cunningham, Elizabeth
    Sosman, Jeffrey A.
    Daud, Adil
    Gonzalez, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) : 3697 - +
  • [6] Association between circulating hepatocyte growth factor (HGF) and clinical response across five studies with the BRAF inhibitor dabrafenib or MEK inhibitor trametinib
    Santiago-Walker, Ademi
    Gagnon, Robert C.
    Carver, Jennifer
    Curtis, C. Martin
    Haney, Patricia
    Little, Shonda Marie
    O'Hagan, Anne
    Goodman, Vicki L.
    Legos, Jeffrey J.
    Patel, Kiran
    Martin, Anne-Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
    Chu, Emily Y.
    Wanat, Karolyn A.
    Miller, Christopher J.
    Amaravadi, Ravi K.
    Fecher, Leslie A.
    Brose, Marcia S.
    McGettigan, Suzanne
    Giles, Lydia R.
    Schuchter, Lynn M.
    Seykora, John T.
    Rosenbach, Misha
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 67 (06) : 1265 - 1272
  • [8] CUTANEOUS SIDE EFFECTS ASSOCIATED WITH BRAF INHIBITOR THERAPY
    Chu, E. Y.
    Wanat, K. A.
    Miller, C. J.
    Amaravadi, R. K.
    Fecher, L. A.
    Brose, M. S.
    McGettigan, S.
    Giles, L. R.
    Schuchter, L. M.
    Seykora, J. T.
    Rosenbach, M.
    JOURNAL OF THE DERMATOLOGY NURSES ASSOCIATION, 2013, 5 (03) : 173 - 173
  • [9] Adverse cutaneous reactions associated with MEK inhibitor therapy in a pediatric population
    Ahmed, Fahad
    Fisher, Michael J.
    Snyder, Kristen M.
    Smith, Katherine
    Laskin, Benjamin L.
    Perman, Marissa J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (05) : 1066 - 1068
  • [10] Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study
    Beckmann, Malte
    Schlueter, Julian
    Erdmann, Michael
    Kramer, Rafaela
    Cunningham, Sarah
    Hackstein, Holger
    Zimmermann, Robert
    Heinzerling, Lucie
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 74 (01)
12345